> ## Content Index
> Fetch the complete content index at: https://www.neurabc.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# China-US BCI Cost Investigation: Near-Zero Cost in Trials, Commercial Threshold to Break
- URL: https://www.neurabc.com/china-us-bci-cost-investigation-near-zero-cost-in-trials-commercial-threshold-to-break/
- Published: 2026-10-31T08:17:23.000Z
- Updated: 2026-10-31T08:17:23.000Z
- Author: zhangguanghua

Brain-computer interface (BCI) technology is accelerating from the lab to clinical application, but the vast majority of global implants are still in the clinical trial phase. At this stage, the out-of-pocket costs for participants are far lower than the public imagines, though clear differences exist in special cases and the early stages of commercialization.

In the US, Neuralink's N1 implant remains available only through clinical trials as of October 2026 and has not been officially commercialized. Officials have explicitly stated that eligible participants bear no financial costs; the device, surgery, and research-related medical care are all covered by the research party. Standard travel and accommodation expenses for the participant and one caregiver are also covered or reimbursed. 

However, there is a clear boundary behind the word "standard". According to media reports, participant CJ (Case 24) is a ventilator-dependent quadriplegic who could not fly commercially and had to use an air ambulance, costing approximately 38,000to52,000 one way. Neuralink explicitly stated it would not cover such extreme transport costs, forcing him to resort to online crowdfunding for the round trip. Crowdfunding for other participants mostly focuses on long-term expenses arising from paralysis itself, such as home modifications and daily care, rather than costs directly generated by the trial.

![](https://storage.ghost.io/c/d7/ad/d7ad0812-3a09-4fff-8aca-bda39840d264/content/images/2026/10/12.png)

Looking ahead to commercialization, Elon Musk has publicly stated the goal is to cap total costs (device plus surgery) at around 5,000,withthedeviceitselfpotentiallydroppingto1,000-2,000aftermassproduction.However,industryestimatesbasedonanalogieswithexistingneuromodulationtechnologieslikedeepbrainstimulationsuggestearlyactualpriceswilllikelyfallinthe50,000 to $100,000 range.

China's BCI development is rapidly advancing. According to company disclosures, StairMed has completed 42 long-term implants, surpassing the number publicly reported by Neuralink; teams from the Center for Excellence in Brain Science and Intelligence Technology (CEBSIT), Chinese Academy of Sciences have also initiated invasive clinical trials. The vast majority of participants in the clinical trial phase do not need to pay out of pocket, as devices, surgeries, and related expenses are covered by research grants or companies. The policy level has already paved the way. Hubei Province, under the guidance of the National Healthcare Security Administration, took the lead in 2025 in issuing medical service price items for BCIs, specifying an invasive implantation fee of 6,552 yuan per procedure, an extraction fee of 3,139 yuan, and a non-invasive adaptation fee of about 966 yuan. Most provinces have formulated similar guide prices, with implantation fees concentrated in the 6,000 to 6,600 yuan range. At the end of 2025, Wuhan Tongji Hospital performed the nation's first surgery executed under this medical service price item (commonly referred to as the "medical insurance price"), but the costs were still covered by research funding, with the patient paying nothing out of pocket.

![](https://storage.ghost.io/c/d7/ad/d7ad0812-3a09-4fff-8aca-bda39840d264/content/images/2026/10/13.png)

Upon entering true commercialization, the cost structure changes significantly. The NEO (Neural Electronic Opportunity) system by Neuracle Technology (Shanghai)—the world's first approved and marketed invasive BCI medical device (epidural implant, mainly for hand function compensation in quadriplegic patients with cervical spinal cord injury)—has a listed price of approximately 475,000 yuan per set. In July 2026, the world's first commercial implantation was completed at Huashan Hospital in Shanghai. Reports indicate the entire system (including rehabilitation support) costs over 400,000 yuan, with the patient paying over 300,000 yuan out of pocket. Currently, the product has not been included in the national basic medical insurance catalog. It is only partially covered in Shanghai through commercial supplementary insurance like Huhuibao, which has an annual cap of 150,000 yuan and pays 30% of the listed price.

Regardless of China or the US, clinical trial participants currently bear almost no costs for devices and surgery; the real potential out-of-pocket expenses are indirect costs like special transportation and long-term daily care. China is at the forefront in terms of price project approval and speed, but commercial products still face a device threshold of hundreds of thousands of yuan. Coverage of the device itself by medical insurance remains a key unresolved issue. As more products gain approval and data accumulates, the cost structure is expected to gradually decrease and be incorporated into a broader payment system.